Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    ORION- D9102C00001 | Recruiting Studies | Interventional Studies
Previous Study | Return to List | Next Study

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) (ORION)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03775486
Recruitment Status : Recruiting
First Posted : December 14, 2018
Last Update Posted : August 28, 2019
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
This is a randomized, double-blind, multi-center, global Phase II study to determine the efficacy and safety of Durvalumab plus Olaparib combination therapy compared with Durvalumab monotherapy as maintenance therapy in patients whose disease has not progressed following Standard of Care (SoC) platinum-based chemotherapy with Durvalumab as first-line treatment in patients with Stage IV non small-cell lung cancer (NSCLC) with tumors that lack activating epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusions.

Condition or disease Intervention/treatment Phase
Non-small Cell Lung Cancer NSCLC Drug: Durvalumab Drug: Placebo for Olaparib Drug: Olaparib Drug: Nab-paclitaxel+carboplatin Drug: Gemcitabine+carboplatin Drug: Pemetrexed+carboplatin Drug: Gemcitabine+cisplatin Drug: Pemetrexed+cisplatin Phase 2

Detailed Description:
Adult patients with a histologically or cytologically documented advanced NSCLC not amenable to curative surgery or radiation with tumors that lack activation EGFR mutations and ALK fusions are eligible for enrollment. During the initial therapy phase, patients will receive treatment with Durvalumab along with the Investigator's choice of platinum-based doublet therapy for squamous NSCLC (nab-paclitaxel plus carboplatin or gemcitabine plus carboplatin/cisplatin) and non-squamous NSCLC (nab-paclitaxel plus carboplatin or pemetrexed plus carboplatin/cisplatin) for 4 cycles. Patients who have completed 4 cycles and not progressed throughout the initial therapy phase will be randomized in a 1:1 ratio into the maintenance phase of the study to receive either Durvalumab plus placebo or Durvalumab plus Olaparib maintenance therapy. Patients will receive maintenance treatment until specific discontinuation criteria are met, including clinical disease progression (as assessed by the Investigator) or RECIST 1.1-defined radiological Progressive Disease (PD), unacceptable toxicity, and withdrawal of consent. Tumor evaluation scans will be performed until objective disease progression as efficacy assessments. All patients will be followed for survival until the end of the study.

Layout table for study information
Study Type : Interventional
Estimated Enrollment : 327 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase II Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab Plus Olaparib Combination Therapy Compared With Durvalumab Monotherapy as Maintenance Therapy in Patients Whose Disease Has Not Progressed Following Standard of Care Platinum-Based Chemotherapy With Durvalumab in First Line Stage IV Non Small Cell Lung Cancer (ORION)
Actual Study Start Date : December 21, 2018
Estimated Primary Completion Date : June 2, 2021
Estimated Study Completion Date : March 8, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
Experimental: Durvalumab/Olaparib Combination Therapy

Durvalumab/Olaparib Combination Therapy:

Durvalumab/SoC chemotherapy (initial therapy phase) followed by Durvalumab/Olaparib (maintenance phase)

Drug: Durvalumab
Initial therapy phase: IV infusion q3w for 4 cycles. Maintenance phase: IV infusion q4w.
Other Name: MEDI4736 (Durvalumab)

Drug: Olaparib
150-mg tablets (2 × 150-mg tablets for 300-mg dose) 100-mg tablet available if dose reductions are required
Other Name: AZD2281 (Olaparib)

Drug: Nab-paclitaxel+carboplatin
Standard of Care chemotherapy (squamous and non-squamous patients)

Drug: Gemcitabine+carboplatin
Standard of Care chemotherapy (squamous patients only)

Drug: Pemetrexed+carboplatin
Standard of Care chemotherapy (non-squamous patients only)

Drug: Gemcitabine+cisplatin
Standard of Care chemotherapy (squamous patients only)

Drug: Pemetrexed+cisplatin
Standard of Care chemotherapy (non-squamous patients only)

Experimental: Durvalumab Monotherapy
Durvalumab Monotherapy: Durvalumab/SoC chemotherapy (initial therapy phase) followed by Durvalumab/placebo (maintenance phase)
Drug: Durvalumab
Initial therapy phase: IV infusion q3w for 4 cycles. Maintenance phase: IV infusion q4w.
Other Name: MEDI4736 (Durvalumab)

Drug: Placebo for Olaparib
Matching tablet
Other Name: Placebo

Drug: Nab-paclitaxel+carboplatin
Standard of Care chemotherapy (squamous and non-squamous patients)

Drug: Gemcitabine+carboplatin
Standard of Care chemotherapy (squamous patients only)

Drug: Pemetrexed+carboplatin
Standard of Care chemotherapy (non-squamous patients only)

Drug: Gemcitabine+cisplatin
Standard of Care chemotherapy (squamous patients only)

Drug: Pemetrexed+cisplatin
Standard of Care chemotherapy (non-squamous patients only)




Primary Outcome Measures :
  1. Progression-free survival [ Time Frame: Approximately 2 years after randomization ]
    Progression-free survival (PFS) defined as time from date of randomization until the date of objective radiological disease progression using RECIST 1.1 or death (by any cause in the absence of progression).


Secondary Outcome Measures :
  1. Overall survival [ Time Frame: Approximately 4 years after randomization ]
    Overall survival (OS) defined as time from date of randomization until the date of death by any cause.

  2. Objective response rate [ Time Frame: Approximately 2 years after randomization. ]
    Objective response rate (ORR) defined as percentage of patients with an Investigator-assessed of complete response (CR) or partial response (PR) after randomization.

  3. Duration of response [ Time Frame: Approximately 2 years after randomization. ]
    Duration of response (DoR) defined as time from the date of first documented response following randomization until the first date of documented progression or death in the absence of disease progression.

  4. PFS in homologous recombination repair related gene mutation (HRRm) population [ Time Frame: Approximately 3 years after randomization ]
    PFS in HRRm population defined as time from date of randomization until the date of objective radiological disease progression in HRRm population using RECIST 1.1 or death (by any cause in the absence of progression).

  5. Concentration of Durvalumab [ Time Frame: PK of Durvalumab will be assessed at 3, 6, 12, 16 and 20 weeks after start of treatment and every 12 weeks thereafter until 3 months after last dose of durvalumab ]
    Concentration of Durvalumab: Pharmacokinetic (PK) of Durvalumab

  6. Change from baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Lung Cancer (LC)13 [ Time Frame: Health-related quality of life (HRQoL) will be assessed at 4 weeks after randomization and every 4 weeks thereafter until 3 months after treatment discontinuation ]
    Disease-related symptoms and HRQoL assessed by change from baseline (for maintenance phase) in EORTC QLQ-LC13.

  7. Change from baseline in EORTC Quality of Life Questionnaire (QLQ) QLQ-C30 [ Time Frame: Health-related quality of life (HRQoL) will be assessed at 4 weeks after randomization and every 4 weeks thereafter until 3 months after treatment discontinuation ]
    Disease-related symptoms and HRQoL assessed by change from baseline (for maintenance phase) in EORTC QLQ-C30

  8. Presence of anti-drug antibodies (ADA) for Durvalumab [ Time Frame: ADA will be assessed at 3, 6, 12, 16 and 20 weeks after start of treatment and every 12 weeks thereafter until 3 and 6 months after last dose of durvalumab ]
    Presence of anti-drug antibodies (ADA) for Durvalumab.

  9. 'Number of Participants with Treatment-Related Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) [ Time Frame: Approximately 2 years after randomization ]
    'Number of Participants with Treatment-Related Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 130 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

- Histologically or cytologically documented Stage IV NSCLC not amenable to curative surgery or radiation.

Patients must have tumors that lack activating EGFR mutations and ALK fusions.

  • (WHO)/(ECOG) performance status of 0 or 1
  • No prior chemotherapy or any other systemic therapy for Stage IV NSCLC
  • Adequate organ and marrow function without blood transfusions in the past 28 days,
  • At least 1 tumor lesion, not previously irradiated, that can be accurately measured as per RECIST 1.1.

Key Inclusion criteria for randomization to maintenance treatment:

  • Documented radiographic evidence of CR, PR, or Stable Disease (SD) as per Investigator-assessed RECIST 1.1 following 4 cycles of platinum-based chemotherapy.
  • Creatinine Clearance (CrCl) ≥51 mL/min calculated by Cockcroft-Gault equation or measured by 24-hour urine collection.
  • Ability to swallow whole oral medications.

Exclusion criteria

  • Mixed small-cell lung cancer and sarcomatoid variant NSCLC histology.
  • Prior exposure to any chemotherapy agents (except chemotherapy or chemoradiation for non-metastatic disease), polyadenosine 5'diphosphoribose [poly (ADP ribose)] polymerase (PARP) therapy, or immunomediated therapy
  • Active or prior documented autoimmune or inflammatory disorders.
  • Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment.
  • Current or prior use of immunosuppressive medication within 14 days before the first dose of Investigational Product (IP)
  • untreated (CNS) metastases and/or carcinomatous meningitis
  • Active infection.

Exclusion criteria to be randomized to maintenance treatment:

• Inability to complete 4 cycles of platinum-based chemotherapy for any reason or discontinuation of Durvalumab during initial therapy.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03775486


Contacts
Layout table for location contacts
Contact: AstraZeneca Clinical Study Information Center 1-877-240-9479 information.center@astrazeneca.com

  Show 77 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Layout table for investigator information
Principal Investigator: Myung-Ju Ahn, MD Sungkyunkwan University School of Medicine, 135-710, Seoul, Korea
Study Director: Mark Lanasa, MD, PHD One MedImmune Way,Gaithersburg,Maryland,United States

Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT03775486     History of Changes
Other Study ID Numbers: D9102C00001
2018-003460-30 ( EudraCT Number )
First Posted: December 14, 2018    Key Record Dates
Last Update Posted: August 28, 2019
Last Verified: August 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by AstraZeneca:
NSCLC
Durvalumab
Olaparib
Maintenance
Homologous Recombination Repair (HRR)
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Gemcitabine
Cisplatin
Carboplatin
Pemetrexed
Durvalumab
Olaparib
Antibodies, Monoclonal
Antineoplastic Agents
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antimetabolites
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors
Antineoplastic Agents, Immunological